In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native ...
As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, ...
Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...
Nevertheless, there is no question that the research credit provides significant tax savings and should be considered by ...
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, ...
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Tenaerts, chief scientific officer, Medable, highlights ...
Session explores innovation in operationalizing clinical trials and how challenges with adoption can be addressed.
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...
In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback